GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vaidya Sane Ayurved Laboratories Ltd (NSE:MADHAVBAUG) » Definitions » Intrinsic Value: Projected FCF

Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Intrinsic Value: Projected FCF : ₹0.00 (As of Jun. 20, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Vaidyane Ayurved Laboratories Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-20), Vaidyane Ayurved Laboratories's Intrinsic Value: Projected FCF is ₹0.00. The stock price of Vaidyane Ayurved Laboratories is ₹148.00. Therefore, Vaidyane Ayurved Laboratories's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Vaidyane Ayurved Laboratories's Intrinsic Value: Projected FCF or its related term are showing as below:

NSE:MADHAVBAUG's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.6
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Vaidyane Ayurved Laboratories Intrinsic Value: Projected FCF Historical Data

The historical data trend for Vaidyane Ayurved Laboratories's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaidyane Ayurved Laboratories Intrinsic Value: Projected FCF Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaidyane Ayurved Laboratories's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaidyane Ayurved Laboratories's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Vaidyane Ayurved Laboratories's Price-to-Projected-FCF falls into.


;
;

Vaidyane Ayurved Laboratories Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Vaidyane Ayurved Laboratories  (NSE:MADHAVBAUG) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Vaidyane Ayurved Laboratories's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=148.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaidyane Ayurved Laboratories Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Vaidyane Ayurved Laboratories's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaidyane Ayurved Laboratories Business Description

Traded in Other Exchanges
N/A
Address
201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution engaged in the treatment of chronic ailments like cardiac disease, diabetes, hypertension, and obesity by combining modern technology with traditional Ayurveda practices. It uses non-invasive, multidisciplinary, and therapies for treating chronic ailments. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management and knee pain relief. The company's business is divided into three segments i.e. Hospital Activity, Sale of Product and Common. It derives maximum revenue from Sale of Products.

Vaidyane Ayurved Laboratories Headlines

No Headlines